Sentence examples for prolongation in time from inspiring English sources

Using CsA as a positive control, we observed a prolongation in time to 50% of maximal response, representing protection from mPTP opening.

HB2 antibody treatment of SCID-HSB-2 mice also led to a significant prolongation in time to leukaemia development compared with sham-treated controls with 37% of animals in this treatment group disease-free at termination of the study.

For radium-223, also a bone targeting agent, there was also a significant prolongation in time to first SSE in the overall trial population and also in the subgroup of patients receiving bisphosphonates [ 82].

The vehicle arm and the celecoxib single agent arm showed shorter times to progression of 5 (4–7) days, n=3 vs 13 (9–14) days, n=3. Figure 2D shows that mice bearing 786-O tumours also exhibit a significant prolongation in time to progression with the combination of sunitinib+celecoxib relative to sunitinib alone (median (range) 16 (12 19) days, n=7 vs 12 (10 13) days, n=7, respectively, P=0.007).

In the heparin PCC preparation we observed a significant concentration-dependent prolongation in coagulation time (CT) and coagulation formation time (CFT), even at the lowest concentration.

The equitoxic doses that led to approximately 50% prolongation in doubling time as compared to untreated cells were chosen for the microarray experiments.

Other drugs were also administered to this patient and together with defervescence during the observation period could have contributed to the prolongation in QTc time.

In our study, a significant prolongation in survival time was seen in patients with HR-positive tumors within cohort B, which consisted of patients diagnosed and treated after the 2001, the year when AIs were first approved in Japan.

Attenuation of cardiovascular, metabolic, and renal function as well as nitrosative stress in response to first-line V2R-antagonist infusion led to a slight prolongation in survival time as compared with AVP and placebo treatment.

Despite diverse strategies for the treatment of patients with extensive SCLC, the results of phase III trials over the past 25 years have shown only a 2-month prolongation in median survival time between patients treated with different regimens (Chute et al, 1999).

The phase 3 study showed a 48% reduction in the mean annual incidence of SRE (P = 0.005), 5 months prolongation in the median time to first SRE (P = 0.009) and 36% reduction in the ongoing risk of SREs at 24 months [6,7].